This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Sialic acid binding Ig-like lectin (SIGLEC)-engaging, tolerance-inducing antigenic liposomes (STALs) to suppress antibody response	Mouse studies identified STALs that could help treat autoimmunity and inflammation. In mice, STALs displaying a protein antigen plus a CD22 ligand, which inhibits autoimmunity, decreased the antigen-specific antibody response during an antigen challenge compared with STALs that only displayed the protein antigen. STALs that had a CD22 ligand inhibited the antibody response by inducing B cell apoptosis. In a mouse model for hemophilia, STALs displaying factor VIII plus a CD22 ligand decreased anti–factor VIII antibody production and bleeding compared with CD22-lacking liposomes. Next steps could include testing the STALs in additional disease indications.	Patent and licensing status unavailable	Macauley, M.S. *et al. J. Clin. Invest.*; published online June 3, 2013; doi:10.1172/JCI69187 **Contact:** James C. Paulson, The Scripps Research Institute, La Jolla, Calif. e-mail: jpaulson@scripps.edu

SciBX 6(25); doi:10.1038/scibx.2013.640
Published online June 27, 2013